陳 美娟

Medicine & Life Sciences

1. SS-A antibodies 100%
2. anti-IgE antibodies 87%
3. Coronavirus 84%
4. Acute Lung Injury 76%
5. Omalizumab 75%
6. Chemotaxis 71%
7. Anti-Idiotypic Antibodies 56%
8. Pneumonia 54%
9. Asthma 52%
10. Interleukin-33 50%
11. Fibrosis 49%
12. Histone Deacetylase Inhibitors 44%
13. Systemic Lupus Erythematosus 42%
14. Interleukin-13 36%
15. Gram-Positive Bacteria 31%
16. B-Lymphocytes 29%
17. Collagen 29%
18. Acids 28%
19. Therapeutics 27%
20. Serum 26%
21. Lung 25%
22. Severe Acute Respiratory Syndrome 24%
23. T-Lymphocytes 23%
24. Adult Respiratory Distress Syndrome 21%
25. Airway Remodeling 19%
26. Plasma Cells 19%
27. Regulatory T-Lymphocytes 19%
28. Cell- and Tissue-Based Therapy 18%
29. Critical Illness 17%
30. Myofibroblasts 17%
31. Monocytes 15%
32. lactate dehydrogenase C4 15%
33. Mortality 15%
34. Stem Cells 14%
35. lipoteichoic acid 13%
36. Plasma Exchange 13%
37. Nephritis 13%
38. Mycophenolic Acid 13%
39. Cytokines 11%
40. Lymphopenia 11%
41. Interleukin-5 10%
42. Pandemics 10%
43. Lung Injury 10%
44. Ferritins 10%
45. Adaptive Immunity 9%
46. Interleukin-1 9%
47. Intravenous Infusions 9%
48. Placenta 8%
49. Innate Immunity 8%
50. Hypoxia 8%